Icecure Medical is trading at $2.26 (-7%) after several weaker sessions amid a modestly cautious market, with no direct catalyst confirmed.
- No new negative company-specific announcement was identified for August 24, 2026; the latest update was positive, announcing IRB approval to begin the ChoICE breast-cancer study.
- Earlier first-half results showed 45% revenue growth but a wider $8.775 million net loss.